Dominari (DOMH) 10-Q 8 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 07, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	DOMINARI HOLDINGS INC.
Entity Central Index Key	0000012239
Entity File Number	001-41845
Entity Tax Identification Number	52-0849320
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	725 5th Avenue
Entity Address, Address Line Two	22nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
Entity Phone Fax Numbers [Line Items]
City Area Code	(212)
Local Phone Number	393-4540
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock ($0.0001 par value per share)
Trading Symbol	DOMH
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		6,276,138

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 3,403	$ 2,833
Marketable securities	3,771	13,547
Deposits with clearing broker	14,181	7,687
Prepaid expenses and other assets	3,121	898
Notes receivable, at fair value - current portion	285	3,177
Total current assets	24,761	28,142
Property and equipment, net	265	344
Notes receivable, at fair value - non-current portion	1,128	1,129
Long Term Equity Investments	13,771	24,150
Right-of-use assets	3,048	3,335
Security deposit	458	458
Total assets	43,431	57,558
Current liabilities
Accounts payable and accrued expenses	1,293	1,036
Accrued salaries and benefits	13	51
Accrued commissions	372	77
Lease liability - current	402	421
Other current liability	336	22
Total current liabilities	2,416	1,607
Lease liability, less current portion	2,748	3,028
Total liabilities	5,164	4,635
Stockholders’ equity
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 6,336,286 and 5,995,065 shares issued as of September 30, 2024 and December 31, 2023, respectively; 6,276,138 and 5,934,917shares outstanding as of September 30, 2024 and December 31, 2023
Additional paid-in capital	263,303	262,187
Treasury stock, as of cost, 60,148 shares as of September 30, 2024 and December 31, 2023	(501)	(501)
Accumulated deficit	(224,535)	(208,763)
Total stockholders’ equity	38,267	52,923
Total liabilities and stockholders’ equity	43,431	57,558
Series D Preferred Stock
Stockholders’ equity
Preferred stock value
Series D-1 Preferred Stock
Stockholders’ equity
Preferred stock value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	6,336,286	5,995,065
Common stock, shares outstanding	6,276,138	5,934,917
Treasury stock, at cost	60,148	60,148
Series D Preferred Stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	3,825	3,825
Preferred stock, shares outstanding	3,825	3,825
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001
Series D-1 Preferred Stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	834	834
Preferred stock, shares outstanding	834	834
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues	$ 4,043	$ 963	$ 11,584	$ 1,034
Operating costs and expenses
General and administrative	7,239	4,067	20,321	16,980
Research and development				3
Total operating expenses	7,239	4,067	20,321	16,983
Loss from operations	(3,196)	(3,104)	(8,737)	(15,949)
Other income (expenses)
Interest income	280	208	729	505
Gain (loss) on marketable securities, net	89	(150)	767	185
Realized and unrealized loss on note receivable, net	(429)		(2,086)	(212)
Change in carrying value of investments	(955)	(495)	(6,445)	(495)
Total other expenses	(1,015)	(437)	(7,035)	(17)
Net loss	$ (4,211)	$ (3,541)	$ (15,772)	$ (15,966)
Net loss per share, basic and diluted
Net loss per share, basic (in Dollars per share)	$ (0.67)	$ (0.66)	$ (2.57)	$ (3.09)
Net loss per share, diluted (in Dollars per share)	$ (0.67)	$ (0.66)	$ (2.57)	$ (3.09)
Weighted average number of shares outstanding, basic and diluted
Weighted average number of shares outstanding, basic (in Shares)	6,328,261	5,345,312	6,129,504	5,159,501
Weighted average number of shares outstanding, diluted (in Shares)	6,328,261	5,345,312	6,129,504	5,159,501

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2022			$ 262,970	$ (3,322)	$ (185,881)	$ 73,767
Balance (in Shares) at Dec. 31, 2022	4,659	5,485,096		468,017
Stock-based compensation			1,485			1,485
Stock-based compensation (in Shares)		529,715
Cancellation of common stock
Cancellation of common stock (in Shares)		(25,000)
Purchase of treasury stock				$ (939)		(939)
Purchase of treasury stock (in Shares)				236,630
Retirement of treasury stock			(3,760)	$ 3,760
Retirement of treasury stock (in Shares)		(644,499)		(644,499)
Net loss					(15,966)	(15,966)
Balance at Sep. 30, 2023			260,695	$ (501)	(201,847)	58,347
Balance (in Shares) at Sep. 30, 2023	4,659	5,345,312		60,148
Balance at Jun. 30, 2023			260,585	$ (501)	(198,306)	61,778
Balance (in Shares) at Jun. 30, 2023	4,659	5,345,312		60,148
Stock-based compensation			110			110
Net loss					(3,541)	(3,541)
Balance at Sep. 30, 2023			260,695	$ (501)	(201,847)	58,347
Balance (in Shares) at Sep. 30, 2023	4,659	5,345,312		60,148
Balance at Dec. 31, 2023			262,187	$ (501)	(208,763)	52,923
Balance (in Shares) at Dec. 31, 2023	4,659	5,995,065		60,148
Stock-based compensation			1,116			1,116
Stock-based compensation (in Shares)		341,221
Net loss					(15,772)	(15,772)
Balance at Sep. 30, 2024			263,303	$ (501)	(224,535)	38,267
Balance (in Shares) at Sep. 30, 2024	4,659	6,336,286		60,148
Balance at Jun. 30, 2024			263,184	$ (501)	(220,324)	42,359
Balance (in Shares) at Jun. 30, 2024	4,659	6,304,183		60,148
Stock-based compensation			119			119
Stock-based compensation (in Shares)		32,103
Net loss					(4,211)	(4,211)
Balance at Sep. 30, 2024			$ 263,303	$ (501)	$ (224,535)	$ 38,267
Balance (in Shares) at Sep. 30, 2024	4,659	6,336,286		60,148

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (15,772)	$ (15,966)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets	287	268
Depreciation	79	57
Change in fair value short-term investments		12
Change in carrying value of long-term investment	6,445	482
Stock-based compensation	1,116	1,485
Realized (gain) loss on marketable securities	(3,762)	1,249
Unrealized (gain) loss on marketable securities	3,361	(897)
Realized and unrealized loss on note receivable	2,086	212
Changes in operating assets and liabilities:
Prepaid expenses and other assets	165	(229)
Prepaid acquisition cost		301
Clearing broker deposits	(6,494)	(3,622)
Accounts payable and accrued expenses	257	(345)
Accrued salaries and benefits	(38)	(628)
Accrued commissions	295	152
Lease liabilities	(299)	11
Other current liabilities	314	66
Notes receivable, at fair value – net interest accrued	58	(96)
Net cash used in operating activities	(11,902)	(17,488)
Cash flows from investing activities
Purchase of marketable securities	(4,007)	(34,068)
Sale of marketable securities	14,767	24,572
Purchase of fixed assets		(419)
Acquisition of FPS, net of cash acquired and receivable owed from FPS		(1,112)
Collection of principal on note receivable	750	850
Loans to employees	(2,390)	(107)
Purchase of short-term and long-term investments	(150)	(75)
Redemption of long-term investments	3,500
Collection of loans to employees	2
Net cash provided by (used in) investing activities	12,472	(10,359)
Cash flows from financing activities
Purchase of treasury stock		(939)
Net cash used in financing activities		(939)
Net increase (decrease) in cash and cash equivalents and restricted cash	570	(28,786)
Cash and cash equivalents, beginning of period	2,833	33,174
Cash and cash equivalents, end of period	$ 3,403	$ 4,388

Organization and Description of

Organization and Description of Business and Recent Developments	9 Months Ended
	Sep. 30, 2024
Organization and Description of Business and Recent Developments [Abstract]
Organization and Description of Business and Recent Developments	Note 1. Organization and Description of Business and Recent Developments Organization and Description of Business Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC. On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the consolidated condensed financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Dominari IM LLC (“Investment Manager”) was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024 the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors. On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

Liquidity and Capital Resources

Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2024
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Note 2. Liquidity and Capital Resources The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2023 Annual Report. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation. Joint Ventures On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2024, there has been no material activity in DFHS. Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024. Leases The Company accounts for its leases under ASC 842, Leases Leases Revenue The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: ● Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. ● Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. ● Other revenue includes revenues such as miscellaneous fees and reimbursed expenses. Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In March 2023, the FASB issued ASU 2023-01, Leases Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2024
Marketable Securities [Abstract]
Marketable Securities	Note 4. Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended September 30, Nine Months Ended 2024 2023 2024 2023 Realized gain (loss) $ 432 $ (762 ) $ 3,762 $ (1,249 ) Unrealized gain (loss) (421 ) 382 (3,361 ) 897 Dividend income 78 230 366 537 Total $ 89 $ (150 ) $ 767 $ 185

Long-Term Equity Investments

Long-Term Equity Investments	9 Months Ended
	Sep. 30, 2024
Long-Term Equity Investments [Abstract]
Long-Term Equity Investments	Note 5. Long-Term Equity Investments The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company’s long-term investments as of September 30, 2024, and December 31, 2023 ($ in thousands): December 31, 2023 September 30, 2024 Cost Basis Carrying Value Cost Basis Carrying Value Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 2,140 $ 4,940 Investment in Kaya Now 1,500 - 1,500 - Investment in Tevva Motors* 1,972 2,794 1,972 - Investment in Unusual Machines 1,075 1,033 - - Investment in Qxpress* 1,000 1,000 1,000 1,000 Investment in Masterclass* 170 170 170 170 Investment in Kraken** 597 597 597 597 Investment in Epic Games* 3,500 3,500 3,500 2,627 Investment in Tesspay** 1,240 2,679 1,240 1,240 Investment in SpaceX* 3,500 4,867 - - Investment in Databricks* 1,200 842 1,200 842 Investment in Discord 476 476 476 476 Investment in Thrasio 300 300 300 - Investment in Automation Anywhere 476 476 476 476 Investment in XAI* - - 100 100 Investment in Cerebras* - - 25 25 Investment in Groq* - - 25 25 Investment in AdvEn - - - 874 Investment in Anduril* 476 476 476 379 Total $ 19,622 $ 24,150 $ 15,197 $ 13,771 * Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. ** Investments made in these companies are through both an SPV and direct investments. The Company recorded an increase in the carrying values of approximately $0.9 million for the three month period ended September 30, 2024 and a decrease in the carrying values of approximately $4.6 million for the nine month period ended September 30, 2024. The Company also recorded a $(0.5) million change in carrying value of investment upon transferring Unusual Machine, Inc shares to marketable securities in addition to the $(6.0) million year to date change from the above table. See Investment in Unusual Machine, Inc below. Investment in SpaceX The Company redeemed its holdings in SpaceX in April of 2024 totaling 36,842 shares of participating membership unites of SpaceX for $3.5 million. This resulted in the Company recording a decrease in the carrying value of the investment for the nine month period ended September 30, 2024. Investment in xAI On May 2, 2024, the Company entered into an agreement (the “xAI Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 100,000 Series XI xAI Units for $0.1 million. Investment in Cerebras On June 17, 2024, the Company entered into an agreement (the “Cerebras Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XI Cerebras Units for $25,000. Investment in Groq On July 25, 2024, the Company entered into an agreement (the “Groq Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for $25,000. Investment in Unusual Machines Unusual Machines, Inc, an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of $4 per share and the shares began trading on the NYSE American under the ticker symbol “UMAC”. As of September 30, 2024, the value of the Company’s holdings in UMAC are presented within the Marketable Securities line item of the financial statements, as the investment has a readily determinable fair value. Investment in Tevva Motors On September 22, 2021, the Company entered into a securities purchase agreement (the “Tevva Motors Subscription Agreement”) with Big Sky Opportunities Fund, LLC, who handled the offering for Tevva Motors. As of December 31, 2023 the investment was valued at $2.8 million. During the second quarter of 2024, the Company identified indicators of impairment for the Tevva investment as a result of liquidity concerns As a result, the Company recorded an impairment charge of approximately $2.8 million and the investment in Tevva was valued at $0 as of September 30, 2024. Investment in Tesspay On March 23, 2022, the Company entered into a securities purchase agreement (the “Tesspay Securities Purchase Agreement”) with Tesspay. Under the Tesspay Securities Purchase Agreement, the Company agreed to purchase 1,000,000 shares of common stock of Tesspay for approximately $0.2 million. The Company also invested an additional $1.0 million for pre-IPO shares with Revere Master SPV LLC-Series VI, who handled the offering for Tesspay. As of December 31, 2023 the investment was valued at $2.7 million. Management noted that Tesspay filed an amendment to its SEC Form S-1 Registration Statement on April 30, 2024 wherein Tesspay disclosed its intent to IPO at between $5.0 and $6.0 price per share. However, given the uncertainty around the probability of the timing of an IPO, the Company has written its investment down to its cost basis. Through the first nine months of 2024 the Company has recorded a decrease in the carrying value of the investment of $1.4 million, with a carrying value of $1.2 million as of September 30, 2024. Investment in Anduril In April 2022, the Company entered into a securities purchase agreement (the “Anduril Securities Purchase Agreement”) with Forge Investments LLC, Fund FG-MHM, who handled the offering of Anduril Industries, Inc. shares, a privately-held defense products company. As of December 31, 2023 the investment was valued at $0.5 million. During the second quarter 2024 review of the investment Dominari noted news activity related to a recent arm’s length funding round, raising $1.5 billion. As a result of this the implied holding value of the investment had decreased slightly per the Company’s independent third-party valuation. As a result, the Company recorded an impairment charge of approximately $0.1 million and the investment in Anduril was valued at $0.4 million as of the third quarter of 2024. Investment in Thrasio In April 2022, the Company entered into a securities purchase agreement (the “Thrasio Securities Purchase Agreement”) with privately-held company Thrasio, LLC, an aggregator of private brands of top Amazon businesses and direct-to-consumer brands. As of December 31, 2023 the investment was valued at $0.3 million. During our first quarter 2024 review of the Thrasio investment Dominari noted news activity related to Thrasio had filed for Chapter 11 bankruptcy protection. As a result, the Company recorded an impairment charge of approximately $0.3 million and the investment in Thrasio was valued at $0 as of September 30, 2024. Investment in Epic Games On March 22, 2022, the Company entered into a securities purchase agreement (the “Epic Games Securities Purchase Agreement”) with Aeon Partners Fund, Series EG, who handled the offering of Epic Games shares. Under the Epic Games Securities Purchase Agreement, the Company agreed to purchase an aggregate of 901 shares of common stock of Epic Games for a total $1.5 million. In April 2022, the Company invested an additional $2 million for the purchase of additional shares of common stock of Epic Games through the Aeon Partners Fund, Series EG. As of December 31, 2023 the investment was valued at $3.5 million. During the Company’s first quarter of 2024 review of the investment Dominari noted a $1.5 billion funding round at a lower price per share than the Company’s initial investment in Epic Games resulting in a $0.9 million decrease in the carrying value of this investment during the nine months ended September 30, 2024. The investment was valued at $2.7 million as of September 30, 2024. Investment in AdvEn On December 26, 2021, the Company entered into a securities purchase agreement (the “AdvEn Securities Purchase Agreement”) with AdvEn Inc. (“AdvEn’), formerly known as Nano Innovations Inc. Under the AdvEn Securities Purchase Agreement, the Company purchased a 10% senior secured convertible promissory note (the “AdvEn Convertible Note”) in the principal amount of $750,000 and warrants (“AdvEn Warrants”, and together with the AdvEn Convertible Note, the “AdvEn Convertible Securities”) permitting the Company to purchase an amount of AdvEn’s common voting shares equal to 50% of the number of common shares issuable upon the conversion of the AdvEn Convertible Note. The Company paid a purchase price of $750,000 for the AdvEn Convertible Note and the AdvEn Warrants. In the fourth quarter of 2022, the Company identified indicators of impairment and recorded an impairment loss on the total investment held. On September 11, 2024, the Company entered into a securities exchange agreement with AdvEn in which the Company agreed to cancel and retire the AdvEn Convertible Securities in exchange for a number of shares of Series D preferred stock of AdvEn equal to 110% of the outstanding amount of the AdvEn Convertible Note that was cancelled multiplied by AdvEn’s initial public offering price, which is convertible into shares and warrants (the “Exchange”) and carries a liquidation preference of $1,000 per share. The investment was valued at $0.9 million as of September 30, 2024.

Notes Receivable

Notes Receivable	9 Months Ended
	Sep. 30, 2024
Notes Receivable [Abstract]
Notes Receivable	Note 6. Notes Receivable The following table presents the Company’s notes receivable as of September 30, 2024 and December 31, 2023 ($ in thousands): September 30, 2024 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8 % $ 250 $ 48 $ 285 Raefan Industries LLC 12/31/2024 8 % $ - $ - $ - American Innovative Robotics 04/01/2027 8 % $ 1,106 $ 23 $ 1,128 Notes receivable, at fair value - current portion $ 285 Notes receivable, at fair value - non-current portion $ 1,128 December 31, 2023 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8 % $ 1,006 $ 58 $ 1,064 Raefan Industries LLC 12/31/2024 8 % $ 1,363 $ 751 $ 2,114 American Innovative Robotics 04/01/2027 8 % $ 1,106 $ 22 $ 1,129 Notes receivable, at fair value - current portion $ 3,177 Notes receivable, at fair value - non-current portion $ 1,129 Convergent Therapeutics, Inc. The Company recorded principal repayment of approximately $0.3 million, interest income of approximately $53,000 and an unrealized loss on the note of approximately $21,000 on the Convergent Convertible Note for the three months ended September 30, 2024. The Company recorded principal repayment of $0.7 million, interest income of approximately $0.2 million on the Convergent Convertible Note for the nine months ended September 30, 2024. Raefan Industries LLC The Company recorded a realized loss as a result of directly writing off approximately $0.4 million and $2.1 million of principal and interest, which the Company deemed uncollectible during the three and nine months ended September 30, 2024, respectively. American Innovative Robotics, LLC The Company recorded interest income of approximately $22,000, and an unrealized loss on the note of approximately $500 on the Robotics Promissory Note for the three months ended September 30, 2024. The Company recorded interest income of approximately $67,000, and an unrealized loss on the note of approximately $1,700 on the Robotics Promissory Note for the nine months ended September 30, 2024.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	9 Months Ended
	Sep. 30, 2024
Fair Value of Financial Assets and Liabilities [Abstract]
Fair Value of Financial Assets and Liabilities	Note 7. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The following table presents the Company’s assets and liabilities that are measured at fair value as of September 30, 2024, and December 31, 2023 ($ in thousands): Fair value measured as of September 30, 2024 Total at Quoted Significant other Significant 2024 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 3,771 $ 3,771 $ - $ - Total marketable securities $ 3,771 $ 3,771 $ - $ - Notes receivable at fair value, current portion $ 285 $ - $ - $ 285 Notes receivable at fair value, non-current portion $ 1,128 $ - $ - $ 1,128 Fair value measured as of December 31, 2023 Total at Quoted Significant other Significant 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 13,547 $ 13,547 $ - $ - Total marketable securities $ 13,547 $ 13,547 $ - $ - Notes receivable at fair value, current portion $ 3,177 $ - $ - $ 3,177 Notes receivable at fair value, non-current portion $ 1,129 $ - $ - $ 1,129 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): September 30, 2024 Notes receivable at fair value, current portion at December 31, 2023 $ 3,177 Collection of principal outstanding (750 ) Realized and unrealized gain (loss) on note receivable, net (2,086 ) Change in interest receivable (56 ) Notes receivable at fair value, current portion at September 30, 2024 $ 285 Notes receivable at fair value, non-current portion at December 31, 2023 $ 1,129 Unrealized gain (loss) on notes receivable (1 ) Notes receivable at fair value, non-current portion at September 30, 2024 $ 1,128 September 30, 2023 Short-term investment at December 31, 2022 $ 13 Change in fair value of investment (12 ) Short-term investment at September 30, 2023 $ 1 Notes receivable at fair value, current portion at December 31, 2022 $ 7,474 Collection of principal outstanding (750 ) Note receivable, Convergent Therapeutics, non-current portion (250 ) Unrealized loss on note receivable (212 ) Accrued interest receivable 74 Notes receivable at fair value, current portion at September 30, 2023 $ 6,336 Notes receivable at fair value, non-current portion at December 31, 2022 $ 1,100 Note receivable, Convergent Therapeutics, non-current portion 250 Accrued interest receivable 22 Notes receivable at fair value, non-current portion at September 30, 2023 $ 1,372 Notes Receivable at fair value As of September 30, 2024, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. For the nine month period ended September 30, 2024 the Company had realized and unrealized losses on notes receivable of $2.1 million and for the three month period ended the Company had realized and unrealized losses on notes receivable of $0.4 million.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Note 8. Leases On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22 nd nd nd On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023. The tables below represent the Company’s lease assets and liabilities as of September 30, 2024: September 30, Assets: Operating lease right-of-use-assets $ 3,048 Liabilities: Current Operating 402 Long-term Operating 2,748 $ 3,150 The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: September 30, Weighted-average remaining lease term – operating leases (in years) 5.7 Weighted-average discount rate – operating leases 10.0 % During the three and nine months ended September 30, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations. Three Months Ended Nine Months Ended September 30, September 30, Operating leases Operating lease cost $ 178 $ 534 Short-term lease rent expense 23 96 Net rent expense $ 201 $ 630 Three Months Ended Nine Months Ended September 30, September 30, Operating leases Operating lease cost $ 179 $ 490 Short-term lease rent expense 33 96 Net rent expense $ 212 $ 586 Supplemental cash flow information related to leases were as follows: Nine Months Ended September 30, Operating cash flows - operating leases $ 548 As of September 30, 2024, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2024 186 Year Ended December 31, 2025 698 Year Ended December 31, 2026 685 Year Ended December 31, 2027 685 Year Ended December 31, 2028 766 Thereafter 1,160 Total 4,180 Less present value discount (1,030 ) Operating lease liabilities $ 3,150

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Net Loss per Share [Abstract]
Net Loss per Share	Note 9. Net Loss per Share Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the nine months ended September 30, 2024, and 2023 are as follows: As of September 30, 2024 2023 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Restricted stock awards 40,000 96,309 Options to purchase common stock 419,988 134,454 Total 904,818 675,593

Stockholders_ Equity and Conver

Stockholders’ Equity and Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Stockholders’ Equity and Convertible Preferred Stock	Note 10. Stockholders’ Equity and Convertible Preferred Stock Common Stock As of September 30, 2024, there are 6,336,286 shares of common stock issued and 6,276,138 shares outstanding. Treasury Stock There are 60,148 shares of treasury stock as of September 30, 2024. Warrants A summary of warrant activity for the three months ended September 30, 2024, is presented below: Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life Outstanding as of December 31, 2023 444,796 $ 29.25 - 2.20 Granted - $ - - - Outstanding as of September 30, 2024 444,796 $ 29.25 - 1.45 Restricted Stock Awards In October 2023, the Company issued an aggregate of 96,311 shares of the Company’s common stock to a member of the Company’s Board of Directors for services rendered. These restricted stock awards were vested in 1/3 increments in annual installments beginning April 13, 2024. During the nine months ended September 30, 2024, 32,103 shares were vested and the remaining shares forfeited. On June 11, 2024, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $0.7 million. See Restricted Stock roll-forward below. A summary of restricted stock awards activity for the nine months ended September 30, 2024, is presented below: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested at December 31, 2023 136,309 $ 2.26 Granted 309,118 $ 2.18 Vested (341,221 ) $ 2.20 Forfeited (64,206 ) $ 2.34 Nonvested at September 30, 2024 40,000 $ 2.07 Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $41,000 and $93,000 for the three months ended September 30, 2024, and 2023, respectively, and $0.8 million and $2.7 million for the nine months ended September 30, 2024 and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses. As of September 30, 2024, there is approximately $82,800 unrecognized stock-based compensation expense related to restricted stock awards. Stock Options A summary of option activity under the Company’s stock option plan for the nine months ended September 30, 2024, is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2023 420,168 $ 5.80 $ - 9.3 Employee options expired (180 ) $ 3,832.72 - - Outstanding as of September 30, 2024 419,988 $ 4.16 $ - 8.5 Options vested and exercisable 156,176 $ 5.43 $ - 8.3 Stock-based compensation associated with the amortization of stock option expense was approximately $0.1 million and $5,000 for the three months ended September 30, 2024, and 2023, respectively, and $0.3 million and $26,000 for the nine months ended September 30, 2024 and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses. Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.2 million.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2024
Revenue [Abstract]
Revenue	Note 11. Revenue The following table presents our total revenue disaggregated by revenue type for the three and nine months ended September 30, 2024 and 2023 (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Underwriting $ 1,971 $ 318 $ 6,360 $ 423 Commissions 1,161 525 3,246 539 Advisory fees 638 72 1,409 72 Other 273 48 569 0 Total $ 4,043 $ 963 $ 11,584 $ 1,034

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Proceedings The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations. In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim. In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

Regulatory

Regulatory	9 Months Ended
	Sep. 30, 2024
Regulatory [Abstract]
Regulatory	Note 13. Regulatory Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of September 30, 2024, Dominari Securities had net capital of approximately $12.46 million, which was approximately $12.31 million in excess of net capital requirement of $0.15 million.

Related Party Transaction

Related Party Transaction	9 Months Ended
	Sep. 30, 2024
Related Party Transaction [Abstract]
Related Party Transaction	Note 14. Related Party Transaction In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023, and currently holds approximately 30% of Revere’s outstanding equity. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned $313,960 and $39,000 in the nine months ending September 30, 2024 and 2023, respectively. The Company incurred referral fees of approximately $45,000 and $80,000 during the three months ending September 30, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 15. Segment Reporting The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido. The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “ Summary of Significant Accounting Policies. The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Nine Months Ended September 30, 2024 Dominari Financial Legacy AIkido Pharma Consolidated Revenue $ 10,553 $ 1,031 $ 11,584 Operating Costs - - - General and administrative 13,183 7,138 20,321 Research and development - - - Loss from operations (2,630 ) (6,107 ) (8,737 ) Other (expenses) income - - - Other income - - - Interest income 545 184 729 Gain on marketable securities - 767 767 Unrealized loss on note receivable - (2,086 ) (2,086 ) Change in fair value of investments - (6,445 ) (6,445 ) Total other (expenses) income 545 (7,580 ) (7,035 ) Net loss $ (2,085 ) $ (13,687 ) $ (15,772 ) Three Months Ended September 30, 2024 Dominari Financial Legacy AIkido Pharma Consolidated Revenue $ 3,684 $ 359 $ 4,043 Operating Costs General and administrative 4,438 2,801 7,239 Research and development - - Loss from operations (754 ) (2,442 ) (3,196 ) Other (expenses) income Other income - - - Interest income 204 76 280 Gain on marketable securities - 89 89 Unrealized loss on note receivable - (429 ) (429 ) Change in fair value of investments - (955 ) (955 ) Total other (expenses) income 204 (1,219 ) (1,015 ) Net loss $ (550 ) $ (3,661 ) $ (4,211 )

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
Income Taxes	Note 16. Income Taxes The Company recorded no As of September 30, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,211)	$ (3,541)	$ (15,772)	$ (15,966)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2024, condensed consolidated statements of operations for the three months and nine months ended September 30, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023. The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.
Joint Ventures	Joint Ventures On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2024, there has been no material activity in DFHS.
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.
Deposits with clearing broker	Deposits with clearing broker Deposits with Dominari Securities’ clearing broker consisted of approximately $14.2 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of September 30, 2024.
Leases	Leases The Company accounts for its leases under ASC 842, Leases Leases
Revenue	Revenue The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers . The following provides detailed information on the recognition of the Company’s revenue from contracts with customers: ● Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income. ● Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date. ● Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet. ● Other revenue includes revenues such as miscellaneous fees and reimbursed expenses.
Long-term equity investments	Long-term equity investments The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
Recently adopted accounting standards	Recently adopted accounting standards In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions In March 2023, the FASB issued ASU 2023-01, Leases
Effect of new accounting pronouncements to be adopted in future periods	Effect of new accounting pronouncements to be adopted in future periods The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Marketable Securities [Abstract]
Schedule of Gains and (Losses) on Marketable Securities	The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months and nine months ended September 30, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands): Three Months Ended September 30, Nine Months Ended 2024 2023 2024 2023 Realized gain (loss) $ 432 $ (762 ) $ 3,762 $ (1,249 ) Unrealized gain (loss) (421 ) 382 (3,361 ) 897 Dividend income 78 230 366 537 Total $ 89 $ (150 ) $ 767 $ 185

Long-Term Equity Investments (T

Long-Term Equity Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Long-Term Equity Investments [Abstract]
Schedule of Long-Term Investments	The following table presents the Company’s long-term investments as of September 30, 2024, and December 31, 2023 ($ in thousands): December 31, 2023 September 30, 2024 Cost Basis Carrying Value Cost Basis Carrying Value Investment in Kerna Health Inc $ 2,140 $ 4,940 $ 2,140 $ 4,940 Investment in Kaya Now 1,500 - 1,500 - Investment in Tevva Motors* 1,972 2,794 1,972 - Investment in Unusual Machines 1,075 1,033 - - Investment in Qxpress* 1,000 1,000 1,000 1,000 Investment in Masterclass* 170 170 170 170 Investment in Kraken** 597 597 597 597 Investment in Epic Games* 3,500 3,500 3,500 2,627 Investment in Tesspay** 1,240 2,679 1,240 1,240 Investment in SpaceX* 3,500 4,867 - - Investment in Databricks* 1,200 842 1,200 842 Investment in Discord 476 476 476 476 Investment in Thrasio 300 300 300 - Investment in Automation Anywhere 476 476 476 476 Investment in XAI* - - 100 100 Investment in Cerebras* - - 25 25 Investment in Groq* - - 25 25 Investment in AdvEn - - - 874 Investment in Anduril* 476 476 476 379 Total $ 19,622 $ 24,150 $ 15,197 $ 13,771 * Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. ** Investments made in these companies are through both an SPV and direct investments.

Notes Receivable (Tables)

Notes Receivable (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Receivable [Abstract]
Schedule of Notes Receivable	The following table presents the Company’s notes receivable as of September 30, 2024 and December 31, 2023 ($ in thousands): Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8 % $ 250 $ 48 $ 285 Raefan Industries LLC 12/31/2024 8 % $ - $ - $ - American Innovative Robotics 04/01/2027 8 % $ 1,106 $ 23 $ 1,128 Notes receivable, at fair value - current portion $ 285 Notes receivable, at fair value - non-current portion $ 1,128 Maturity Date Stated Interest Rate Principal Amount Interest Receivable Fair Value Notes receivable, at fair value Convergent convertible note 12/2/2024 8 % $ 1,006 $ 58 $ 1,064 Raefan Industries LLC 12/31/2024 8 % $ 1,363 $ 751 $ 2,114 American Innovative Robotics 04/01/2027 8 % $ 1,106 $ 22 $ 1,129 Notes receivable, at fair value - current portion $ 3,177 Notes receivable, at fair value - non-current portion $ 1,129

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value of Financial Assets and Liabilities [Abstract]
Schedule of Assets and Liabilities that are Measured at Fair Value	The following table presents the Company’s assets and liabilities that are measured at fair value as of September 30, 2024, and December 31, 2023 ($ in thousands): Fair value measured as of September 30, 2024 Total at Quoted Significant other Significant 2024 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 3,771 $ 3,771 $ - $ - Total marketable securities $ 3,771 $ 3,771 $ - $ - Notes receivable at fair value, current portion $ 285 $ - $ - $ 285 Notes receivable at fair value, non-current portion $ 1,128 $ - $ - $ 1,128 Fair value measured as of December 31, 2023 Total at Quoted Significant other Significant 2023 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 13,547 $ 13,547 $ - $ - Total marketable securities $ 13,547 $ 13,547 $ - $ - Notes receivable at fair value, current portion $ 3,177 $ - $ - $ 3,177 Notes receivable at fair value, non-current portion $ 1,129 $ - $ - $ 1,129
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Notes receivable at fair value, current portion at December 31, 2023 $ 3,177 Collection of principal outstanding (750 ) Realized and unrealized gain (loss) on note receivable, net (2,086 ) Change in interest receivable (56 ) Notes receivable at fair value, current portion at September 30, 2024 $ 285 Notes receivable at fair value, non-current portion at December 31, 2023 $ 1,129 Unrealized gain (loss) on notes receivable (1 ) Notes receivable at fair value, non-current portion at September 30, 2024 $ 1,128 Short-term investment at December 31, 2022 $ 13 Change in fair value of investment (12 ) Short-term investment at September 30, 2023 $ 1 Notes receivable at fair value, current portion at December 31, 2022 $ 7,474 Collection of principal outstanding (750 ) Note receivable, Convergent Therapeutics, non-current portion (250 ) Unrealized loss on note receivable (212 ) Accrued interest receivable 74 Notes receivable at fair value, current portion at September 30, 2023 $ 6,336 Notes receivable at fair value, non-current portion at December 31, 2022 $ 1,100 Note receivable, Convergent Therapeutics, non-current portion 250 Accrued interest receivable 22 Notes receivable at fair value, non-current portion at September 30, 2023 $ 1,372

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Lease Assets and Liabilities	The tables below represent the Company’s lease assets and liabilities as of September 30, 2024: September 30, Assets: Operating lease right-of-use-assets $ 3,048 Liabilities: Current Operating 402 Long-term Operating 2,748 $ 3,150
Schedule of Quantitative Information about the Company’s Operating Leases	The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842: September 30, Weighted-average remaining lease term – operating leases (in years) 5.7 Weighted-average discount rate – operating leases 10.0 %
Schedule of lease Expense to Current Period Operations	During the three and nine months ended September 30, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations. Three Months Ended Nine Months Ended September 30, September 30, Operating leases Operating lease cost $ 178 $ 534 Short-term lease rent expense 23 96 Net rent expense $ 201 $ 630 Three Months Ended Nine Months Ended September 30, September 30, Operating leases Operating lease cost $ 179 $ 490 Short-term lease rent expense 33 96 Net rent expense $ 212 $ 586
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases were as follows: Nine Months Ended September 30, Operating cash flows - operating leases $ 548
Schedule of Future Minimum Payments	As of September 30, 2024, future minimum payments during the next five years and thereafter are as follows: Operating Leases Remaining Period Ended December 31, 2024 186 Year Ended December 31, 2025 698 Year Ended December 31, 2026 685 Year Ended December 31, 2027 685 Year Ended December 31, 2028 766 Thereafter 1,160 Total 4,180 Less present value discount (1,030 ) Operating lease liabilities $ 3,150

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Net Loss per Share [Abstract]
Schedule of Computation of Diluted Loss Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the nine months ended September 30, 2024, and 2023 are as follows: As of September 30, 2024 2023 Convertible preferred stock 34 34 Warrants to purchase common stock 444,796 444,796 Restricted stock awards 40,000 96,309 Options to purchase common stock 419,988 134,454 Total 904,818 675,593

Stockholders_ Equity and Conv_2

Stockholders’ Equity and Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the three months ended September 30, 2024, is presented below: Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life Outstanding as of December 31, 2023 444,796 $ 29.25 - 2.20 Granted - $ - - - Outstanding as of September 30, 2024 444,796 $ 29.25 - 1.45
Schedule of Restricted Stock Awards Activity	A summary of restricted stock awards activity for the nine months ended September 30, 2024, is presented below: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested at December 31, 2023 136,309 $ 2.26 Granted 309,118 $ 2.18 Vested (341,221 ) $ 2.20 Forfeited (64,206 ) $ 2.34 Nonvested at September 30, 2024 40,000 $ 2.07
Schedule of Stock Option Plan	A summary of option activity under the Company’s stock option plan for the nine months ended September 30, 2024, is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2023 420,168 $ 5.80 $ - 9.3 Employee options expired (180 ) $ 3,832.72 - - Outstanding as of September 30, 2024 419,988 $ 4.16 $ - 8.5 Options vested and exercisable 156,176 $ 5.43 $ - 8.3

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue [Abstract]
Schedule of Total Revenue Disaggregated by Revenue Type	The following table presents our total revenue disaggregated by revenue type for the three and nine months ended September 30, 2024 and 2023 (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Underwriting $ 1,971 $ 318 $ 6,360 $ 423 Commissions 1,161 525 3,246 539 Advisory fees 638 72 1,409 72 Other 273 48 569 0 Total $ 4,043 $ 963 $ 11,584 $ 1,034

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss	The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Nine Months Ended September 30, 2024 Dominari Financial Legacy AIkido Pharma Consolidated Revenue $ 10,553 $ 1,031 $ 11,584 Operating Costs - - - General and administrative 13,183 7,138 20,321 Research and development - - - Loss from operations (2,630 ) (6,107 ) (8,737 ) Other (expenses) income - - - Other income - - - Interest income 545 184 729 Gain on marketable securities - 767 767 Unrealized loss on note receivable - (2,086 ) (2,086 ) Change in fair value of investments - (6,445 ) (6,445 ) Total other (expenses) income 545 (7,580 ) (7,035 ) Net loss $ (2,085 ) $ (13,687 ) $ (15,772 ) Three Months Ended September 30, 2024 Dominari Financial Legacy AIkido Pharma Consolidated Revenue $ 3,684 $ 359 $ 4,043 Operating Costs General and administrative 4,438 2,801 7,239 Research and development - - Loss from operations (754 ) (2,442 ) (3,196 ) Other (expenses) income Other income - - - Interest income 204 76 280 Gain on marketable securities - 89 89 Unrealized loss on note receivable - (429 ) (429 ) Change in fair value of investments - (955 ) (955 ) Total other (expenses) income 204 (1,219 ) (1,015 ) Net loss $ (550 ) $ (3,661 ) $ (4,211 )

Organization and Description _2

Organization and Description of Business and Recent Developments (Details) - USD ($) $ in Millions		9 Months Ended
	Oct. 04, 2022	Sep. 30, 2024	Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]
Seller paid (in Dollars)	$ 2
Additional seller paid (in Dollars)		$ 1.4
FPS Purchase Agreement [Member]
Organization and Description of Business and Recent Developments [Line Items]
Membership interests	20%	80%	100%
Dominari Financial Heritage Strategies LLC [Member]
Organization and Description of Business and Recent Developments [Line Items]
Ownership interests		50%

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) $ in Millions	Sep. 30, 2024 USD ($)
Summary of Significant Accounting Policies [Line Items]
Money market funds	$ 14.2
Dominari Financial Heritage Strategies LLC [Member]
Summary of Significant Accounting Policies [Line Items]
Interest rate	50%

Marketable Securities (Details)

Marketable Securities (Details) - Schedule of Gains and (Losses) on Marketable Securities - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Gains and (Losses) on Marketable Securities [Abstract]
Realized gain (loss)	$ 432	$ (762)	$ 3,762	$ (1,249)
Unrealized gain (loss)	(421)	382	(3,361)	897
Dividend income	78	230	366	537
Total	$ 89	$ (150)	$ 767	$ 185

Long-Term Equity Investments (D

Long-Term Equity Investments (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 11, 2024

Jul. 25, 2024

Jun. 17, 2024

May 02, 2024

Mar. 23, 2022

Mar. 22, 2022

Dec. 26, 2021

Apr. 30, 2024

Sep. 30, 2024

Jun. 30, 2024

Mar. 31, 2024

Sep. 30, 2024

Dec. 31, 2023

Feb. 14, 2024

Apr. 30, 2022

Long-Term Equity Investments [Line Items]

Unrealized losses on long term investments

$ 900,000

$ 4,600,000

Investment

500,000

500,000

Marketable securities

6,000,000

6,000,000

Investment in SpaceX [Member]

Long-Term Equity Investments [Line Items]

Redeemed shares (in Shares)

36,842

Redeemed shares, value

$ 3,500,000

Investment in XAI [Member]

Long-Term Equity Investments [Line Items]

Redeemed shares, value

$ 100,000

Agreed to purchase shares (in Shares)

100,000

Investment in Cerebras [Member]

Long-Term Equity Investments [Line Items]

Redeemed shares, value

$ 25,000

Agreed to purchase shares (in Shares)

25,000

Investment in Groq [Member]

Long-Term Equity Investments [Line Items]

Redeemed shares, value

$ 25,000

Agreed to purchase shares (in Shares)

25,000

Investment in Unusual Machines [Member]

Long-Term Equity Investments [Line Items]

Public offering price (in Dollars per share)

$ 4

Investment in Tevva Motors [Member]

Long-Term Equity Investments [Line Items]

Investment value

0

$ 2,800,000

Impairment charge

2,800,000

Investment in Tesspay [Member]

Long-Term Equity Investments [Line Items]

Agreed to purchase shares (in Shares)

1,000,000

Investment value

1,200,000

2,700,000

Common stock value

$ 200,000

Invested an additional amount

$ 1,000,000

Unrealized loss on investment

1,400,000

Investment in Anduril [Member]

Long-Term Equity Investments [Line Items]

Investment value

$ 400,000

500,000

Fund raising

1,500,000,000

Impairment charge

$ 100,000

Investment in Thrasio [Member]

Long-Term Equity Investments [Line Items]

Investment value

0

300,000

Impairment charge

300,000

Investment in Epic Games [Member]

Long-Term Equity Investments [Line Items]

Agreed to purchase shares (in Shares)

901

Investment value

$ 1,500,000

2,700,000

$ 3,500,000

Invested an additional amount

$ 2,000,000

Unrealized loss on investment

900,000

Fund raising

$ 1,500,000,000

Investment in AdvEn [Member]

Long-Term Equity Investments [Line Items]

Investment

$ 900,000

$ 900,000

Senior secured convertible

10%

Principal amount

$ 750,000

Common shares percentage

50%

Purchase price amount

$ 750,000

Liquidation preference per share (in Dollars per share)

$ 1,000

Minimum [Member]

Long-Term Equity Investments [Line Items]

Market price (in Dollars per share)

$ 5

Maximum [Member]

Long-Term Equity Investments [Line Items]

Market price (in Dollars per share)

$ 6

Series D Preferred Stock [Member]

Long-Term Equity Investments [Line Items]

Liquidation preference per share (in Dollars per share)

$ 0.0001

$ 0.0001

$ 0.0001

Series D Preferred Stock [Member] | Investment in AdvEn [Member]

Long-Term Equity Investments [Line Items]

Common shares percentage

110%

Long-Term Equity Investments _2

Long-Term Equity Investments (Details) - Schedule of Long-Term Investments - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		$ 15,197	$ 19,622
Long-term investments, Carrying Value		13,771	24,150
Investment In Kerna Health Inc [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		2,140	2,140
Long-term investments, Carrying Value		4,940	4,940
Investment in Kaya Now [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		1,500	1,500
Long-term investments, Carrying Value
Investment in Tevva Motors [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	1,972	1,972
Long-term investments, Carrying Value	[1]		2,794
Investment in Unusual Machines [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis			1,075
Long-term investments, Carrying Value			1,033
Investment in Qxpress [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	1,000	1,000
Long-term investments, Carrying Value	[1]	1,000	1,000
Investment in Masterclass [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	170	170
Long-term investments, Carrying Value	[1]	170	170
Investment in Kraken [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[2]	597	597
Long-term investments, Carrying Value	[2]	597	597
Investment in Epic Games [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	3,500	3,500
Long-term investments, Carrying Value	[1]	2,627	3,500
Investment in Tesspay [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[2]	1,240	1,240
Long-term investments, Carrying Value	[2]	1,240	2,679
Investment in SpaceX [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]		3,500
Long-term investments, Carrying Value			4,867	[1]
Investment in Databricks [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	1,200	1,200
Long-term investments, Carrying Value		842	842	[1]
Investment in Discord [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		476	476
Long-term investments, Carrying Value		476	476
Investment in Thrasio [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		300	300
Long-term investments, Carrying Value			300
Investment in Automation Anywhere [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis		476	476
Long-term investments, Carrying Value		476	476
Investment in XAI [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	100
Long-term investments, Carrying Value		100		[1]
Investment in Cerebras [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	25
Long-term investments, Carrying Value		25		[1]
Investment in Groq [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	25
Long-term investments, Carrying Value		25		[1]
Investment in AdvEn [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis
Long-term investments, Carrying Value		874
Investment in Anduril [Member]
Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	[1]	476	476
Long-term investments, Carrying Value		$ 379	$ 476	[1]
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. Investments made in these companies are through both an SPV and direct investments.

Notes Receivable (Details)

Notes Receivable (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Convergent Therapeutics, Inc. [Member]
Notes Receivable [Line Items]
Principal repayment	$ 300,000	$ 700,000
Interest income	53,000	200,000
Unrealized loss	21,000
Raefan Industries LLC [Member]
Notes Receivable [Line Items]
Unrealized loss	400,000	2,100,000
American Innovative Robotics, LLC [Member]
Notes Receivable [Line Items]
Interest income	22,000	67,000
Unrealized loss	$ 500	$ 1,700

Notes Receivable (Details) - Sc

Notes Receivable (Details) - Schedule of Notes Receivable - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule of Notes Receivable [Line Items]
Notes receivable, at fair value - current portion	$ 285	$ 3,177
Notes receivable, at fair value - non-current portion	$ 1,128	$ 1,129
Convergent convertible note [Member]
Schedule of Notes Receivable [Line Items]
Maturity Date	Dec. 02, 2024	Dec. 02, 2024
Stated Interest Rate	8%	8%
Principal Amount	$ 250	$ 1,006
Interest Receivable	48	58
Fair Value	$ 285	$ 1,064
Raefan Industries LLC [Member]
Schedule of Notes Receivable [Line Items]
Maturity Date	Dec. 31, 2024	Dec. 31, 2024
Stated Interest Rate	8%	8%
Principal Amount		$ 1,363
Interest Receivable		751
Fair Value		$ 2,114
American Innovative Robotics [Member]
Schedule of Notes Receivable [Line Items]
Maturity Date	Apr. 01, 2027	Apr. 01, 2027
Stated Interest Rate	8%	8%
Principal Amount	$ 1,106	$ 1,106
Interest Receivable	23	22
Fair Value	$ 1,128	$ 1,129

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Fair Value of Financial Assets and Liabilities [Abstract]
Unrealized losses	$ 0.4	$ 2.1
Realized losses	$ 0.4

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Schedule of Assets and Liabilities are Measured at Fair Value [Line items]
Equities	$ 3,771	$ 13,547
Total marketable securities	3,771	13,547
Notes receivable at fair value, current portion	285	3,177
Notes receivable at fair value, non-current portion	1,128	1,129
Quoted prices in active markets (Level 1) [Member]
Schedule of Assets and Liabilities are Measured at Fair Value [Line items]
Equities	3,771	13,547
Total marketable securities	3,771	13,547
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant other observable inputs (Level 2) [Member]
Schedule of Assets and Liabilities are Measured at Fair Value [Line items]
Equities
Total marketable securities
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant unobservable inputs (Level 3) [Member]
Schedule of Assets and Liabilities are Measured at Fair Value [Line items]
Equities
Total marketable securities
Notes receivable at fair value, current portion	285	3,177	$ 6,336	$ 7,474
Notes receivable at fair value, non-current portion	$ 1,128	$ 1,129	$ 1,372	$ 1,100

Fair Value of Financial Asset_5

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis - Level 3 [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Notes receivable at fair value, current portion, Balance beginning	$ 3,177	$ 7,474
Notes receivable at fair value, non-current portion Balance beginning	1,129	1,100
Short-term investment at December 31, 2022		13
Collection of principal outstanding	(750)	(750)
Unrealized loss on note receivable		(212)
Accrued interest receivable		74
Realized and unrealized gain (loss) on note receivable, net	(2,086)
Change in interest receivable	(56)
Notes receivable at fair value, current portion at Balance ending	285	6,336
Unrealized gain (loss) on notes receivable	(1)
Notes receivable at fair value, non-current portion Balance ending	$ 1,128	1,372
Accrued interest receivable		22
Change in fair value of investment		(12)
Short-term investment at September 30, 2023		1
Convergent Therapeutics [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Note receivable, Convergent Therapeutics, non-current portion		(250)
Notes receivable at fair value, non-current portion Balance ending		$ 250

Leases (Details)

Leases (Details) - USD ($)			3 Months Ended		9 Months Ended
	Jan. 11, 2023	Sep. 23, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jul. 11, 2022
Leases [Line Items]
Lease term		7 years					7 years
Lease rent expenses	$ 12,874
Increase rent amount		$ 51,868			$ 13,502
Rent payment		$ 49,368
Lease expenses			$ 201,000	$ 212,000	$ 630,000	$ 586,000

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets:
Operating lease right-of-use-assets	$ 3,048	$ 3,335
Liabilities:
Operating Current	402	421
Long-term
Operating Long-term	2,748	$ 3,028
Total	$ 3,150

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Quantitative Information about the Company’s Operating Leases	Sep. 30, 2024
Schedule of Quantitative Information about the Company’s Operating Leases [Abstract]
Weighted-average remaining lease term – operating leases (in years)	5 years 8 months 12 days
Weighted-average discount rate – operating leases	10%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease Expense to Current Period Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule Of Lease Expense [Abstract]
Operating lease cost	$ 178	$ 179	$ 534	$ 490
Short-term lease rent expense	23	33	96	96
Net rent expense	$ 201	$ 212	$ 630	$ 586

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]
Operating cash flows - operating leases	$ 548

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of Future Minimum Payments $ in Thousands	Sep. 30, 2024 USD ($)
Schedule of Future Minimum Payments [Abstract]
Remaining Period Ended December 31, 2024	$ 186
Year Ended December 31, 2025	698
Year Ended December 31, 2026	685
Year Ended December 31, 2027	685
Year Ended December 31, 2028	766
Thereafter	1,160
Total	4,180
Less present value discount	(1,030)
Operating lease liabilities	$ 3,150

Net Loss Per Share (Details) -

Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Computation of Diluted Loss Per Share [Line Items]
Total diluted loss per share	904,818	675,593
Convertible preferred stock [Member]
Schedule of Computation of Diluted Loss Per Share [Line Items]
Total diluted loss per share	34	34
Warrants to purchase common stock [Member]
Schedule of Computation of Diluted Loss Per Share [Line Items]
Total diluted loss per share	444,796	444,796
Restricted stock awards [Member]
Schedule of Computation of Diluted Loss Per Share [Line Items]
Total diluted loss per share	40,000	96,309
Options to purchase common stock [Member]
Schedule of Computation of Diluted Loss Per Share [Line Items]
Total diluted loss per share	419,988	134,454

Stockholders_ Equity and Conv_3

Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 11, 2024	Oct. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Common stock, shares issued (in Shares)			6,336,286		6,336,286		5,995,065
Common stock outstanding (in Shares)			6,276,138		6,276,138		5,934,917
Treasury stock shares (in Shares)			60,148		60,148		60,148
Vested and the remaining shares forfeited (in Shares)					32,103
Total fair value	$ 700,000
Share based compensation expense			$ 100,000	$ 5,000	$ 300,000	$ 26,000
Unrecognized stock-based compensation expense			82,800		82,800
Estimated future stock-based compensation expense					200,000
Restricted Stock Awards [Member]
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Share based compensation expense			$ 41,000	$ 93,000	$ 800,000	$ 2,700,000
Common Stock [Member]
Stockholders’ Equity and Convertible Preferred Stock [Line Items]
Aggregate shares (in Shares)		96,311
Granted shares (in Shares)	154,559

Stockholders_ Equity and Conv_4

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)		9 Months Ended
	Dec. 31, 2023	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, ending balance	444,796	444,796
Weighted Average per share, ending balance	$ 29.25	$ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life	2 years 2 months 12 days	1 year 5 months 12 days
Granted, Warrants
Granted, Weighted Average Exercise Price
Granted, Total Intrinsic Value
Granted, Weighted Average Remaining Contractual Life

Stockholders_ Equity and Conv_5

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Restricted Stock Awards Activity [Line Items]
Number of shares, beginning balance | shares	136,309
Weighted Average per share, beginning balance | $ / shares	$ 2.26
Number of Restricted Stock Awards, Granted | shares	309,118
Weighted Average Grant Day Fair Value, Granted | $ / shares	$ 2.18
Number of Restricted Stock Awards, Vested | shares	(341,221)
Weighted Average Grant Day Fair Value, Vested | $ / shares	$ 2.2
Number of Restricted Stock Awards, Forfeited | shares	(64,206)
Weighted Average Grant Day Fair Value, Forfeited | $ / shares	$ 2.34
Number of shares, ending balance | shares	40,000
Weighted Average per share, ending balance | $ / shares	$ 2.07

Stockholders_ Equity and Conv_6

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Plan - USD ($)		9 Months Ended
	Dec. 31, 2023	Sep. 30, 2024
Schedule of Stock Option Activity [Abstract]
Outstanding ending balance, Number of Shares	420,168	419,988
Outstanding ending balance, Weighted Average Exercise Price	$ 5.8	$ 4.16
Outstanding ending balance, Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life (in years)	9 years 3 months 18 days	8 years 6 months
Number of Shares, Options vested and exercisable		156,176
Weighted Average Exercise Price, Options vested and exercisable		$ 5.43
Total Intrinsic Value, Options vested and exercisable
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable		8 years 3 months 18 days
Employee options expired, Number of Shares		(180)
Employee options expired, Weighted Average Exercise Price		$ 3,832.72
Employee options expired, Intrinsic Value
Employee options expired , Weighted Average Remaining Contractual Life (in years)

Revenue (Details) - Schedule of

Revenue (Details) - Schedule of Total Revenue Disaggregated by Revenue Type - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]
Total revenue disaggregated	$ 4,043	$ 963	$ 11,584	$ 1,034
Underwriting [Member]
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]
Total revenue disaggregated	1,971	318	6,360	423
Commissions [Member]
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]
Total revenue disaggregated	1,161	525	3,246	539
Advisory fees [Member]
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]
Total revenue disaggregated	638	72	1,409	72
Other [Member]
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]
Total revenue disaggregated	$ 273	$ 48	$ 569	$ 0

Regulatory (Details)

Regulatory (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Regulatory [Line Items]
Net capital requirement	$ 12,460
Excess amount	12,310
Minimum [Member]
Regulatory [Line Items]
Net capital requirement	$ 150

Related Party Transaction (Deta

Related Party Transaction (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2023
Related Party Transaction [Abstract]
Revere’s outstanding equity percentage	30%
Incurred fees	$ 313,960	$ 45,000	$ 80,000	$ 39,000

Segment Reporting (Details)

Segment Reporting (Details)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Reportable segments	2

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Loss - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Dominari Financial [Member]
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]
Revenue	$ 3,684	$ 10,553
Operating Costs
General and administrative	4,438	13,183
Research and development
Loss from operations	(754)	(2,630)
Other (expenses) income
Other income
Interest income	204	545
Gain on marketable securities
Unrealized loss on note receivable
Change in fair value of investments
Total other (expenses) income	204	545
Net loss	(550)	(2,085)
Legacy AIkido Pharma [Member]
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]
Revenue	359	1,031
Operating Costs
General and administrative	2,801	7,138
Research and development
Loss from operations	(2,442)	(6,107)
Other (expenses) income
Other income
Interest income	76	184
Gain on marketable securities	89	767
Unrealized loss on note receivable	(429)	(2,086)
Change in fair value of investments	(955)	(6,445)
Total other (expenses) income	(1,219)	(7,580)
Net loss	(3,661)	(13,687)
Consolidated [Member]
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss [Line Items]
Revenue	4,043	11,584
Operating Costs
General and administrative	7,239	20,321
Research and development
Loss from operations	(3,196)	(8,737)
Other (expenses) income
Other income
Interest income	280	729
Gain on marketable securities	89	767
Unrealized loss on note receivable	(429)	(2,086)
Change in fair value of investments	(955)	(6,445)
Total other (expenses) income	(1,015)	(7,035)
Net loss	$ (4,211)	$ (15,772)

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Taxes [Abstract]
Income tax expense